American Century Companies Inc. Raises Stock Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS)

American Century Companies Inc. boosted its position in Keros Therapeutics, Inc. (NASDAQ:KROS) by 10.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 328,920 shares of the company’s stock after purchasing an additional 31,251 shares during the quarter. American Century Companies Inc.’s holdings in Keros Therapeutics were worth $5,207,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. AlphaQuest LLC grew its position in shares of Keros Therapeutics by 469.0% in the 4th quarter. AlphaQuest LLC now owns 3,596 shares of the company’s stock worth $57,000 after buying an additional 2,964 shares during the period. Exchange Traded Concepts LLC bought a new stake in Keros Therapeutics during the fourth quarter worth about $99,000. China Universal Asset Management Co. Ltd. grew its holdings in Keros Therapeutics by 19.0% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,589 shares of the company’s stock worth $136,000 after purchasing an additional 1,372 shares during the period. Handelsbanken Fonder AB increased its stake in shares of Keros Therapeutics by 11.3% during the fourth quarter. Handelsbanken Fonder AB now owns 10,800 shares of the company’s stock valued at $171,000 after purchasing an additional 1,100 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Keros Therapeutics by 59.0% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,371 shares of the company’s stock valued at $312,000 after purchasing an additional 1,994 shares during the last quarter. Hedge funds and other institutional investors own 71.56% of the company’s stock.

Analysts Set New Price Targets

KROS has been the topic of several recent research reports. Truist Financial cut their price target on Keros Therapeutics from $100.00 to $43.00 and set a “buy” rating on the stock in a research note on Monday, December 23rd. William Blair downgraded Keros Therapeutics from an “outperform” rating to a “market perform” rating in a report on Thursday, December 12th. Oppenheimer reduced their price target on Keros Therapeutics from $63.00 to $23.00 and set an “outperform” rating for the company in a report on Thursday, January 16th. Wedbush reaffirmed a “neutral” rating and issued a $15.00 price target on shares of Keros Therapeutics in a research report on Tuesday. Finally, Wells Fargo & Company cut their price objective on shares of Keros Therapeutics from $28.00 to $26.00 and set an “overweight” rating on the stock in a research report on Thursday, February 27th. Six equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $42.33.

Keros Therapeutics Stock Down 2.9 %

KROS opened at $9.98 on Friday. Keros Therapeutics, Inc. has a twelve month low of $9.41 and a twelve month high of $72.37. The firm has a 50 day moving average price of $11.00 and a 200-day moving average price of $32.99. The stock has a market capitalization of $404.81 million, a price-to-earnings ratio of -1.92 and a beta of 1.39.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings results on Wednesday, February 26th. The company reported ($1.14) earnings per share for the quarter, beating the consensus estimate of ($1.36) by $0.22. The firm had revenue of $3.04 million for the quarter, compared to analysts’ expectations of $37.32 million. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. As a group, analysts expect that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current year.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.